Compare Crispr Therapeutics AG (CRSP) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ArcelorMittal SA — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.17B), while ArcelorMittal SA trades at $73.73 (market cap $55.96B). The key difference: ArcelorMittal SA is far larger — about 10.8× Crispr Therapeutics AG's market cap, and ArcelorMittal SA pays a 0.81% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MT | |
|---|---|---|
Market Cap | $5.17B | $55.96B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $75.35 |
52-Week Low | $44.34 | $32.44 |
Enterprise Value | $3.59B | $65.53B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
ArcelorMittal (MT) trades at $73.29, up 0.1% with bullish technical signals from moving averages despite recent earnings miss. The company shows improving fundamentals with Q2 2026 revenue growth and strong cash flow generation of $4.8B from operations. Recent corporate developments include dividend payments and strategic partnerships with Microsoft, while analyst consensus remains positive with 50% buy ratings.
Outlook remains cautiously optimistic with European business recovery potential, though risks include cyclical steel demand volatility and elevated debt levels. The stock offers value with reasonable P/S (0.89) and P/B (1.01) ratios, but investors should monitor execution on second-half shipment guidance and margin pressures from input costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
